Theseus Pharmaceuticals, Inc. THRX
Feb 13, 2024, 3:59 PM EST
52-week range unavailable
- Market cap
- 181.50M
- Shares out
- 44.65M
- Forward P/E
- -3.79
- Volume
- 677.69K
- Open
- 4.06
- Previous close
- 4.07
- Day's range
- 4.06 – 4.07
- Beta
- 3.98
- Analysts
- Hold
- Price target
- 5.25 (+29.2%)
- Earnings date
- Mar 14, 2024
Key statistics
- Enterprise value
- -22.45M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -31.67M
- Total cash
- 205.12M
- Total debt
- 3.66M
- Return on equity
- -25.55%
- Short % of float
- 1.91%
- 50-day average
- 4.02
- 200-day average
- 4.47
Analyst view
Consensus: hold
- Target (low)
- 3.50
- Target (mean)
- 5.25
- Target (high)
- 7.00
- Strong buy0
- Buy1
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 14, 2024
Expected Mar 14, 2024. Consensus EPS estimate -0.29.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 14, 2024 | Dec 1, 2023 | -0.33 | — | — | — |
| Nov 17, 2023 | Sep 1, 2023 | -0.35 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.34 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -0.42 | — | — | — |
| Mar 9, 2023 | Dec 1, 2022 | -0.44 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | -0.34 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 13, 2023 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jul 13, 2023 | Wedbush | main | Outperform | Outperform |
| Jul 13, 2023 | Needham | down | Buy | Hold |
| Jul 13, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| May 25, 2023 | Needham | reit | Buy | Buy |
| May 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- theseusrx.com
News
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Stocks That Hit 52-Week Lows On Tuesday 
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 - Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
- Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2022 - Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on THRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLACKSON TIMOTHY P | Chief Executive Officer | Purchase | Nov 10, 2022 | 351,030 |
| DAHMS BRADFORD D | Chief Financial Officer | Purchase | Nov 29, 2022 | 6,142 |
| FORESITE CAPITAL MANAGEMENT V, LLC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 16, 2023 | 0 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 16, 2023 | 0 |
| HAYDEN DONALD J JR | Director | Purchase | Dec 29, 2022 | 10,000 |
| OMEGA FUND VI, L.P | Former | Purchase | Oct 11, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 39.52% | 17,233,668 | 160.79M | Jun 29, 2023 |
| Foresite Capital Management V, LLC | 8.22% | 3,585,346 | 33.45M | Jun 29, 2023 |
| Frazier Life Sciences Management, L.P. | 5.16% | 2,248,194 | 20.98M | Jun 29, 2023 |
| Paradigm Biocapital Advisors LP | 4.47% | 1,950,327 | 18.20M | Jun 29, 2023 |
| Deerfield Management Company, L.P. (Series C) | 3.21% | 1,400,352 | 13.07M | Jun 29, 2023 |
| Blackrock Inc. | 3.06% | 1,333,868 | 12.44M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Health Sciences Fund | 2.23% | 970,942 | 9.06M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 1.07% | 466,802 | 1.47M | Aug 30, 2023 |
| Vanguard Total Stock Market Index Fund | 0.93% | 405,973 | 3.79M | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.49% | 211,791 | 1.98M | Jun 29, 2023 |
| Fidelity Small Cap Index Fund | 0.41% | 177,355 | 597.69K | Jul 30, 2023 |
| iShares Russell 2000 Value ETF | 0.41% | 179,385 | 563.27K | Aug 30, 2023 |